X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Through the acquisition, Azurity gains access to Slayback's pipeline including, Precedex (dexmedetomidine hydrochloride), an alpha2-adrenergic agonist with sedative properties used for short-term intravenous sedation.
Lead Product(s): Dexmedetomidine Hydrochloride
Therapeutic Area: Neurology Product Name: Precedex-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Azurity Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition September 27, 2023
Details:
Slayback’s Brimonidine Tartrate Ophthalmic Solution 0.025%, the private label equivalent of Lumify® in U.S. Lumify® is an over-the-counter (OTC) eyedrop that can be used to relieve redness of the eye due to minor eye irritations.
Lead Product(s): Brimonidine Tartrate
Therapeutic Area: Ophthalmology Product Name: Brimonidine Tartrate-Generic
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Dr. Reddy\'s Laboratories
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement July 29, 2022
Details:
Lumify® is an over-the-counter (OTC) eyedrop having Brimonidine Tartrate that can be used to relieve redness of the eye due to minor eye irritations. The agreement also provides Dr. Reddy’s exclusive rights to the product outside the U.S.
Lead Product(s): Brimonidine Tartrate
Therapeutic Area: Ophthalmology Product Name: Brimonidine Tartrate-Generic
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Dr. Reddy\'s Laboratories
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement July 29, 2022
Details:
U.S.FDA has approved Abbreviated New Drug Application for Merzee (Slayback Pharma), an AB-rated generic equivalent of Taytulla® (Allergan), an estrogen/progestin combination oral contraceptive indicated for use by women to prevent pregnancy.
Lead Product(s): Norethisterone Acetate,Ethinyl Estradiol,Ferrous Fumarate
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Merzee
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Lupin Ltd
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 07, 2022
Details:
Sandoz in-licensed Icatibant injection, a critical anti-inflammatory medicine used to treat acute attacks of hereditary angioedema, from Slayback Pharma. Deal allows Sandoz to further grow its injectable medicine portfolio and supply another important medicine to US patients.
Lead Product(s): Icatibant Acetate
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Sandoz B2B
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 28, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
